Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00296816 · ClinicalTrials.gov registry record · Phase 2
TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
A Phase 2 study of Ovarian Cancer, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
- 1
- Study location
NCT00296816: Completed Phase 2 study of Ovarian Cancer, sponsored by Sanofi.
NCT00296816 is a Phase 2 study of Ovarian Cancer that has completed, run by Sanofi. The registered enrollment target is 132 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00296816, a Phase 2 study of Ovarian Cancer, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
- 1
- Study location
Study Summary
Feasibility study to assess a novel combination of cytotoxic agents, docetaxel and oxaliplatin, as first-line therapy in the treatment of ovarian cancer and the impact of angiogenesis inhibition for the progression and prognosis of ovarian cancer by concurrent addition of bevacizumab (Avastin®).
Primary Outcome
Tumor assessments were performed by Computed tomography (CT) and Magnetic Resonance Imaging (MRI) to evaluate disease progression based on Gynecologic Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST). Disease progression was recorded as any one of the following: * appearance of a new lesion * symptomatic deterioration * progression of target or nontarget lesions * death Participants who did not die or show show disease progression achieved PFS. PFS rate is the percen
Conditions Studied
Interventions
- DRUG Bevacizumab (Avastin®)
- DRUG Docetaxel (Taxotere®)
- DRUG Oxaliplatin (Eloxatin®)
Study Locations (1)
New Jersey
- Sanofi-Aventis Administrative Office - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2006-03 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
What the finished NCT00296816 record still lists
NCT00296816 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab (Avastin®) is the first listed.
NCT00296816 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00296816 about?
NCT00296816 is a clinical study titled "TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary". Feasibility study to assess a novel combination of cytotoxic agents, docetaxel and oxaliplatin, as first-line therapy in the treatment of ovarian cancer and the impact of angiogenesis inhibition for the progression and prognosis of ovarian cancer by concurrent addition of bevacizumab (Avastin®).
What is the current status of trial NCT00296816?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2006-03. Estimated completion is 2011-08.
What conditions does trial NCT00296816 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT00296816?
The interventions under investigation include: Bevacizumab (Avastin®) (DRUG), Docetaxel (Taxotere®) (DRUG), Oxaliplatin (Eloxatin®) (DRUG).
Who is sponsoring clinical trial NCT00296816?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00296816 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00296816's enrollment target sits among peer trials
132 129th of 322 higher than 194 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia